Scholar Rock Holding Corporatio (SRRK) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $46.81. The rating moved from Neutral to Oversold on October 1, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$46.81
• Last changeMoved from Neutral to Oversold on October 1, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Scholar Rock Holding Corporatio (SRRK) is a clinical-stage biotech with program-specific catalysts that can drive binary moves in the stock. Financial runway, timing of clinical readouts, and execution on regulatory paths are the primary drivers for near-term performance, while payer/pricing dynamics and competition shape longer-term commercial prospects. Given current market risk-off sentiment and limited short-term conviction absent fresh data, expect subdued trading with episodic volatility around any trial or corporate news.

Key factors

• Clinical-stage pipeline with upcoming catalysts that could materially revalue the stock if positive data are reported
• Specialty-biotech investor appetite for late-stage biologics provides episodic support for valuation
• Cash runway and recent capital raises (if any) will determine near-term dilution risk and ability to fund trials
• Macro risk-off tone and light volumes limit near-term upside absent clear clinical or commercial news
• Policy backdrop (Medicare drug-price negotiation) elevates potential long-term pricing pressure for novel therapies

Risks

• Clinical trial setbacks or negative readouts that would sharply reduce valuation
• Need to raise capital leading to dilution at lower prices if cash runway is limited
• Adverse regulatory decisions or slower-than-expected approval timelines
• Downward pricing pressure from payer reforms or negotiations reducing future revenue potential
• Competition from larger biopharma programs and platform technologies that could erode market share
• Sector-wide risk-off episodes that reduce liquidity and amplify share price volatility

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.